Immunocore Holdings (IMCR) EBIT Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted EBIT Margin of 6.82% for Q1 2026, up 136.21% sequentially from 18.85% in Q4 2025, and up 1068.0% YoY from 0.58% in Q1 2025.
Powered by 
Analysis
Immunocore Holdings (IMCR) EBIT Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported EBIT Margin for 6 years, with the latest figure at 6.82% in Q1 2026.
- Quarterly EBIT Margin rose 1068.0% year-over-year to 6.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.35% (up 592.0% YoY) and the FY2025 annual result came in at 11.34%, up 1138.0% from the prior year.
- EBIT Margin grew to 6.82% in Q1 2026 per IMCR's latest filing, from 18.85% in the prior quarter.
- Over five years, EBIT Margin peaked at 14.98% in Q3 2022 and troughed at 51.43% in Q2 2022.
- A 5-year average of 19.97% and a median of 21.53% in 2023 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin soared 53743 bps in 2022, then slumped 3679 bps in 2023.
- Over 5 years, EBIT Margin stood at 46.45% in 2022, then soared by 48 bps to 24.3% in 2023, then advanced by 5 bps to 23.14% in 2024, then climbed by 19 bps to 18.85% in 2025, then jumped by 136 bps to 6.82% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 6.82%, 18.85%, and 6.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | -2.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.58% |
| Mar 31, 2026 | 6.82% |
| Dec 31, 2025 | -18.85% |
| Sep 30, 2025 | -6.92% |
| Jun 30, 2025 | -15.18% |
| Mar 31, 2025 | -3.85% |
| Dec 31, 2024 | -23.14% |
| Sep 30, 2024 | -10.59% |
| Jun 30, 2024 | -21.24% |
| Mar 31, 2024 | -37.57% |
| Dec 31, 2023 | -24.30% |
| Sep 30, 2023 | -21.81% |
| Jun 30, 2023 | -33.03% |
| Mar 31, 2023 | -26.89% |
| Dec 31, 2022 | -46.45% |
| Sep 30, 2022 | 14.98% |
| Jun 30, 2022 | -51.43% |
| Dec 31, 2021 | -573.82% |
| Sep 30, 2021 | -522.45% |